Life AI Net
首页
资讯库
计算器
目录
周刊
Hot
登录
简体中文
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
首页
资讯库
计算器
目录
周刊
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
登录
首页
资讯库
计算器
目录
More
滚动资讯
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
FierceBiotech
Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech
Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Lonza News
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus
Lonza News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com
Lonza News
Simulations Plus partners with Lonza and FDA on drug formulation research - Investing.com
BioWorld
Japanese researchers report new μ-opioid receptor antagonists
BioWorld
Incyte discloses new TYK2 and/or JAK1 inhibitors
BioWorld
Insilico Medicine divulges new NLRP3 inflammasome inhibitors
BioWorld
Neolaia synthesizes new CD38 inhibitors
资讯库
搜索
搜索
最新
最旧
清除
@BioWorld
总数
1057
来源
BioWorld
搜索
--
BioWorld
2026年4月14日
Mayinglong Pharmaceutical presents new 5-HT4 receptor agonists
BioWorld
2026年4月14日
New LPAR1 antagonists reported in Haisco patent
BioWorld
2026年4月13日
CMS looks to bring Rx prior authorization into digital age
BioWorld
2026年4月13日
Appointments and advancements for April 13, 2026
BioWorld
2026年4月13日
Financings for April 13, 2026
BioWorld
2026年4月13日
In the clinic for April 13, 2026
BioWorld
2026年4月13日
Other news to note for April 13, 2026
BioWorld
2026年4月13日
Regulatory actions for April 13, 2026
BioWorld
2026年4月13日
Biggest gainers and losers for April 6-10, 2026
BioWorld
2026年4月13日
Chengdu Diao Pharmaceutical discloses new apelin receptor agonists
BioWorld
2026年4月13日
Gluetacs Therapeutics identifies SMARCA2/4 degraders
BioWorld
2026年4月13日
Fit and fat: Study shows no such thing as metabolically healthy obesity
BioWorld
2026年4月10日
Second CRL for Replimune’s RP-1 for melanoma
BioWorld
2026年4月10日
Money raised by biopharma
BioWorld
2026年4月10日
Biopharma money raised: Jan. 1-April 9, 2026
BioWorld
2026年4月10日
In the clinic for April 10, 2026
BioWorld
2026年4月10日
Other news to note for April 10, 2026
BioWorld
2026年4月10日
Regulatory actions for April 10, 2026
上一页
4 / 59
下一页